HACKENSACK, N.J.–(BUSINESS WIRE)–ReGen Biologics (OTC: RGBO) (“ReGen” or “the company”) reported that the first commercial surgery in the U.S. utilizing its Menaflex collagen meniscus implant was completed on Wednesday April 15, 2009.
The surgery was performed at Jewish Hospital & St. Mary’s HealthCare in Louisville, Kentucky by David Caborn, M.D., for a patient who had a partial meniscectomy four years previously. Dr. Caborn commented on the procedure, “The Menaflex implant represents a much needed new treatment option for patients with meniscus deficiency. I am excited about the potential for the Menaflex procedure to decrease pain, improve function and decrease the reoperation rate in this patient population.”
Also commenting was Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO of ReGen, “We are delighted that Dr. Caborn performed the first U.S. Menaflex procedure. He is a distinguished surgeon who is committed to meniscus preservation.”
Surgeons who have attended the ReGen surgical training program are listed on the Menaflex website (www.menaflex.com) to assist with patient awareness and education.